Structure–Activity Relationship of 5-mer Catalytides, GSGYR and RYGSG
Abstract
:1. Introduction
2. Materials and Methods
2.1. Peptide Preparation
2.2. Stereo-Structure Analysis
2.3. Proteolytic Activities
2.4. Thioflavin-T (ThT) Assay
2.5. Low-Vacuum Scanning Electron Microscopy (LV-SEM)
2.6. Docking Simulation
2.7. Statistical Analysis
3. Results and Discussions
3.1. Stereo-Structure Analysis of 5-mer Peptides
3.2. Proteolytic Activity of GSGYR and RYGSG Peptides
3.3. Thioflavin (ThT) Assay
3.4. Scanning Electron Microscopy (SEM)
3.5. Docking Simulation
4. Conclusions
5. Patents
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Nakamura, R.; Konishi, M.; Taniguchi, M.; Hatakawa, Y.; Akizawa, T. The discovery of shorter synthetic proteolytic peptides derived from Tob1 protein. Peptides 2019, 116, 71–77. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, R.; Konishi, M.; Hatakawa, Y.; Saito, M.; Akizawa, T. The Novel Catalytic Peptide, A Synthetic Nona-Peptide (JAL-TA9) Derived from Tob1 Protein, Digests the Amyloid-β Peptide. J. Royal. Sci. 2019, 1, 30–35. [Google Scholar]
- Dahlgren, K.N.; Manelli, A.M.; Blaine Stine, W.; Baker, L.K.; Krafft, G.A.; Ladu, M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277, 32046–32053. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scheuner, D.; Eckman, C.; Jensen, M.; Song, X.; Citron, M.; Suzuki, N.; Bird, T.D.; Hardy, J.; Hutton, M.; Kukull, W.; et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s Disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s Disease. Nat. Med. 1996, 2, 864–870. [Google Scholar] [CrossRef]
- Doody, R.S.; Thomas, R.G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P.S.; et al. Phase 3 trials of Solanezumab for mild-to-moderate Alzheimer’s Disease. N. Eng. J. Med. 2014, 370, 311–321. [Google Scholar] [CrossRef] [PubMed]
- Young, L.M.; Saunders, J.C.; Mahood, R.A.; Revill, C.H.; Foster, R.J.; Tu, L.H.; Raleigh, D.P.; Radford, S.E.; Ashcroft, A.E. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nat. Chem. 2015, 7, 73–81. [Google Scholar] [CrossRef] [PubMed]
- Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; et al. The antibody Aducanumab reduces Aβ plaques in Alzheimer’s Disease. Nature 2016, 537, 50–56. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, R.; Konishi, M.; Higashi, Y.; Saito, M.; Akizawa, T. Comparison of the catalytic activities of 5-mer synthetic peptides derived from Box A region of Tob/BTG family proteins against the Amyloid-Beta fragment peptides. Integr. Mol. Med. 2019, 6, 1–4. [Google Scholar] [CrossRef] [Green Version]
- Matsuda, S.; Kawamura-Tsuzuku, J.; Ohsugi, M.; Yoshida, M.; Emi, M.; Nakamura, Y.; Onda, M.; Yoshida, Y.; Nishiyama, A.; Yamamoto, T. Tob, a novel protein that interacts with P185erbB2, is associated with anti-proliferative activity. Oncogene 1996, 12, 705–713. [Google Scholar]
- Kumar, J.; Namsechi, R.; Sim, V.L. Structure-based peptide design to modulate Amyloid Beta aggregation and reduce cytotoxicity. PLoS ONE 2015, 10, e0129087. [Google Scholar] [CrossRef] [Green Version]
- Schulze-Topphof, U.; Casazza, S.; Varrin-Doyer, M.; Pekarek, K.; Sobe, R.A.; Hauser, S.L.; Oksenberg, J.R.; Zamvil, S.S.; Baranzini, S.E. Tob1 plays a critical role in the activation of encephalitogenic t cells in Cns autoimmunity. J. Exp. Med. 2013, 210, 1301–1309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, Y.; Wang, C.; Wu, J.; Li, L. BTG/Tob Family Members Tob1 and Tob2 inhibit proliferation of mouse embryonic stem cells via Id3 mRNA degradation. Biochem. Biophys. Res. Commun. 2015, 462, 208–214. [Google Scholar] [CrossRef] [PubMed]
- Winkler, G.S. The mammalian anti-proliferative BTG/Tob protein family. J. Cell. Physiol. 2010, 222, 66–72. [Google Scholar] [CrossRef] [PubMed]
- Yang, X.; Morita, M.; Wang, H.; Suzuki, T.; Yang, W.; Luo, Y.; Zhao, C.; Yu, Y.; Bartlam, M.; Yamamoto, T.; et al. Crystal structures of human BTG2 and mouse TIS21 involved in suppression of CAF1 deadenylase activity. Nucleic Acids Res. 2008, 36, 6872–6881. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Horiuchi, M.; Takeuchi, K.; Noda, N.; Muroya, N.; Suzuki, T.; Nakamura, T.; Kawamura-Tsuzuku, J.; Takahasi, K.; Yamamoto, T.; Inagaki, F. Structural basis for the antiproliferative activity of the Tob-HCaf1 complex. J. Biol. Chem. 2009, 284, 13244–13255. [Google Scholar] [CrossRef] [Green Version]
- Hatakawa, Y.; Nakamura, R.; Konishi, M.; Sakane, T.; Saito, M.; Akizawa, T. Catalytides derived from the Box A region in the ANA/BTG3 protein cleave Amyloid-β fragment peptide. Heliyon 2019, 5, e02454. [Google Scholar] [CrossRef] [Green Version]
- Takai, E.; Ohashi, G.; Ueki, R.; Yamada, Y.; Fujita, J.I.; Shiraki, K. Scanning electron microscope imaging of amyloid fibrils. Am. J. Biochem. Biotechnol. 2014, 10, 31–39. [Google Scholar] [CrossRef] [Green Version]
- Hedstrom, L. Serine protease mechanism and specificity. Chem. Rev. 2002, 102, 4501–4523. [Google Scholar] [CrossRef]
- Bulic, B.; Pickhardt, M.; Mandelkow, E.M.; Mandelkow, E. Tau protein and Tau aggregation inhibitors. Neuropharmacology 2010, 59, 276–289. [Google Scholar] [CrossRef]
- Lee, H.J.; Choi, C.; Lee, S.J. Membrane-bound α-Synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 2002, 277, 671–678. [Google Scholar] [CrossRef] [Green Version]
- Dawson, T.M.; Dawson, V.L. Rare genetic mutations shed light on the pathogenesis of Parkinson Disease. J. Clin. Investig. 2003, 111, 145–151. [Google Scholar] [CrossRef]
- Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the α-Synuclein gene identified in families with Parkinson’s Disease. Science 1997, 276, 2045–2047. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Uversky, V.N.; Fink, A.L. Effect of familial Parkinson’s Disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-Synuclein. Biochemistry 2001, 40, 11604–11613. [Google Scholar] [CrossRef] [PubMed]
- McAlary, L.; Aquilina, J.A.; Yerbury, J.J. Susceptibility of mutant SOD1 to form a destabilized monomer predicts cellular aggregation and toxicity but not in vitro aggregation propensity. Front. Neurosci. 2016, 10, 499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, E.B.; Lee, V.M.Y.; Trojanowski, J.Q. Gains or Losses: Molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 2012, 13, 38–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zuo, X.; Zhou, J.; Li, Y.; Wu, K.; Chen, Z.; Luo, Z.; Zhang, X.; Liang, Y.; Esteban, M.A.; Zhou, Y.; et al. TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. Nat. Struct. Mol. Biol. 2021, 28, 132–142. [Google Scholar] [CrossRef] [PubMed]
- Kojima, A.; Konishi, M.; Akizawa, T. Prion fragment peptides are digested with membrane type matrix metalloproteinases and acquire enzyme resistance through Cu2+-binding. Biomolecules 2014, 4, 510–526. [Google Scholar] [CrossRef] [Green Version]
- Sakaguchi, Y.; Nakamura, R.; Konishi, M.; Hatakawa, Y.; Toyoda, H.; Akizawa, T. Effects of Cu2+ on conformational change and aggregation of HPrP180-192 with a V180I mutation of the prion protein. Biochem. Biophys. Res. Commun. 2019, 514, 798–802. [Google Scholar] [CrossRef]
- Nakamura, R.; Konishi, M.; Sakaguchi, Y.; Hatakawa, Y.; Tanaka, A.; Sakane, T.; Saito, M.; Akizawa, T. JAL-TA9 inhibits aggregation of Hprp180-192 through the cleavage reaction. J. Pharm. Pharmacol. Res. 2020, 4, 23–33. [Google Scholar] [CrossRef]
- Prusiner, S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216, 136–144. [Google Scholar] [CrossRef] [Green Version]
- Schmitz, M.; Cramm, M.; Llorens, F.; Candelise, N.; Müller-Cramm, D.; Varges, D.; Schulz-Schaeffer, W.J.; Zafar, S.; Zerr, I. Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie. Sci. Rep. 2016, 6, 28711. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nakamura, R.; Akizawa, T.; Konishi, M. Structure–Activity Relationship of 5-mer Catalytides, GSGYR and RYGSG. Biomolecules 2022, 12, 1766. https://doi.org/10.3390/biom12121766
Nakamura R, Akizawa T, Konishi M. Structure–Activity Relationship of 5-mer Catalytides, GSGYR and RYGSG. Biomolecules. 2022; 12(12):1766. https://doi.org/10.3390/biom12121766
Chicago/Turabian StyleNakamura, Rina, Toshifumi Akizawa, and Motomi Konishi. 2022. "Structure–Activity Relationship of 5-mer Catalytides, GSGYR and RYGSG" Biomolecules 12, no. 12: 1766. https://doi.org/10.3390/biom12121766